Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant docetaxel-capecitabine-oxaliplatin study in Siewert III cardia adenocarcinoma
2015-003572-79Phase 2Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Sep 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, capecitabine and oxaliplatin in gastroesophageal junction adenocarcinoma, sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Overall survival over 3 years from enrollment. Started Sep 2021; status: terminated.
02
Drugs
docetaxelcapecitabineoxaliplatin
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2015-003572-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003572-79.